Research has identified a potential strategy to overcome drug resistance in breast cancer, involving the use of a CDK2 inhibitor called BLU-222 in combination with CDK4/6 inhibitors. This approach may enhance antitumor activity, although the specific details and outcomes are not entirely clear. The study's findings may have implications for treatment options, but the relationship to other cancer types, such as ovarian and prostate cancer, and other treatments is uncertain.